Basic Information
RNALocate ID: | RLID:11001972 |
RNA Symbol: | hsa-miR-190a-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-190 |
RNA ID: | miRBase:MIMAT0000458 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20615901 |
Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
Method: | Microarray|RT-PCR |
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11001968 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11001969 | Exosome | Brain tissue | 23382797 |
RLID:11001970 | Exosome | Plasma | 23663360 |
RLID:11001971 | Exosome | Plasma | 24683445 |
RLID-D:11000386 | Microvesicle | Colon cancer cell line (LIM1863)|Mesenchymal stem cells|Urine | |
RLID-D:11001184 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-190a-5p | Cardiomyopathies | MNDR-E-MI-22104 |
MNDR | hsa-miR-190a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-22105 |
MNDR | hsa-miR-190a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-22106 |
MNDR | hsa-miR-190a-5p | Medulloblastoma | MNDR-E-MI-22107 |
MNDR | hsa-miR-190a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-22108 |
MNDR | hsa-miR-190a-5p | Lymphoma non-hodgkin | MNDR-E-MI-22109 |
MNDR | hsa-miR-190a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-22110 |
MNDR | hsa-miR-190a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-22111 |
MNDR | hsa-miR-190a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-22112 |
MNDR | hsa-miR-190a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-22113 |
MNDR | hsa-miR-190a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-22114 |
MNDR | hsa-miR-190a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-22115 |
MNDR | hsa-miR-190a-5p | Dermatomyositis | MNDR-E-MI-22116 |
MNDR | hsa-miR-190a-5p | Prostate cancer | MNDR-E-MI-22117 |
MNDR | hsa-miR-190a-5p | Gastric cancer | MNDR-E-MI-22118 |
MNDR | hsa-miR-190a-5p | Alzheimer disease | MNDR-E-MI-22119 |
MNDR | hsa-miR-190a-5p | Esophageal carcinoma | MNDR-E-MI-22120 |
MNDR | hsa-miR-190a-5p | Dysautonomia familial | MNDR-E-MI-22121 |
MNDR | hsa-miR-190a-5p | Ataxia telangiectasia | MNDR-E-MI-22122 |
MNDR | hsa-miR-190a-5p | Huntington disease | MNDR-E-MI-22123 |
MNDR | hsa-miR-190a-5p | Lung cancer | MNDR-E-MI-22124 |
MNDR | hsa-miR-190a-5p | Parkinson disease | MNDR-E-MI-22125 |
MNDR | hsa-miR-190a-5p | Breast cancer | MNDR-E-MI-22126 |
MNDR | hsa-miR-190a-5p | Thyroid cancer | MNDR-E-MI-22127 |
MNDR | hsa-miR-190a-5p | Pancreatic cancer | MNDR-E-MI-22128 |
MNDR | hsa-miR-190a-5p | Melanoma | MNDR-E-MI-22129 |
MNDR | hsa-miR-190a-5p | Nephroblastoma | MNDR-E-MI-22130 |
MNDR | hsa-miR-190a-5p | Colon cancer | MNDR-E-MI-22131 |
MNDR | hsa-miR-190a-5p | Colon adenocarcinoma | MNDR-E-MI-22132 |
MNDR | hsa-miR-190a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-22133 |
MNDR | hsa-miR-190a-5p | Ovarian neoplasms | MNDR-E-MI-22134 |
MNDR | hsa-miR-190a-5p | Prostate adenocarcinoma | MNDR-E-MI-22135 |
MNDR | hsa-miR-190a-5p | Carcinoma ductal breast | MNDR-E-MI-22136 |
MNDR | hsa-miR-190a-5p | Glioblastoma | MNDR-E-MI-22137 |
MNDR | hsa-miR-190a-5p | Glioma | MNDR-E-MI-22138 |
MNDR | hsa-miR-190a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-22139 |
MNDR | hsa-miR-190a-5p | Epilepsy temporal lobe | MNDR-E-MI-22140 |
MNDR | hsa-miR-190a-5p | Liposarcoma | MNDR-E-MI-22141 |
MNDR | hsa-miR-190a-5p | Inclusion body myositis | MNDR-E-MI-22142 |
MNDR | hsa-miR-190a-5p | Meningioma | MNDR-E-MI-22143 |
MNDR | hsa-miR-190a-5p | Uterine cancer | MNDR-E-MI-22144 |
MNDR | hsa-miR-190a-5p | Gastric adenocarcinoma | MNDR-E-MI-22145 |
MNDR | hsa-miR-190a-5p | Lung squamous cell carcinoma | MNDR-E-MI-22146 |
MNDR | hsa-miR-190a-5p | Non-small cell lung adenocarcinoma | MNDR-E-MI-22147 |
MNDR | hsa-miR-190a-5p | Lung adenocarcinoma | MNDR-E-MI-22148 |
MNDR | hsa-miR-190a-5p | Thyroid carcinoma | MNDR-E-MI-22149 |
MNDR | hsa-miR-190a-5p | Bladder urothelial carcinoma | MNDR-E-MI-22150 |
MNDR | hsa-miR-190a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-22151 |
MNDR | hsa-miR-190a-5p | Carcinoma renal cell | MNDR-E-MI-22152 |
MNDR | hsa-miR-190a-5p | Renal clear cell carcinoma | MNDR-E-MI-22153 |
MNDR | hsa-miR-190a-5p | Esophageal cancer | MNDR-E-MI-22154 |
MNDR | hsa-miR-190a-5p | HIV | MNDR-E-MI-22155 |
MNDR | hsa-miR-190a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-22156 |
MNDR | hsa-miR-190a-5p | Breast invasive carcinoma | MNDR-E-MI-22157 |
MNDR | hsa-miR-190a-5p | Hepatocellular carcinoma | MNDR-E-MI-22158 |
MNDR | hsa-miR-190a-5p | B-cell lymphoma | MNDR-E-MI-22159 |
MNDR | hsa-miR-190a-5p | T-cell leukemia | MNDR-E-MI-22160 |
MNDR | hsa-miR-190a-5p | Neuromyelitis optica | MNDR-E-MI-22161 |
MNDR | hsa-miR-190a-5p | Acute myelogenous leukemia | MNDR-E-MI-22162 |
MNDR | hsa-miR-190a-5p | Colorectal cancer | MNDR-E-MI-22163 |
MNDR | hsa-miR-190a-5p | Acute lymphocytic leukemia | MNDR-E-MI-22164 |
MNDR | hsa-miR-190a-5p | Ependymoma | MNDR-E-MI-22165 |
MNDR | hsa-miR-190a-5p | Prostatic neoplasms | MNDR-E-MI-22166 |
MNDR | hsa-miR-190a-5p | Arsenic poisoning | MNDR-E-MI-22167 |
MNDR | hsa-miR-190a-5p | Stroke lacunar | MNDR-E-MI-22168 |
MNDR | hsa-miR-190a-5p | Breast cancer her3+ negative | MNDR-E-MI-22169 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CDKN1B | Homo sapiens | RR00311901 |
TOP